As of Thursday close, Nektar Therapeutics’s (NASDAQ:NKTR) stock was down -$0.05, moving down -6.26 percent to $0.72. The average number of shares traded per day over the past five days has been 7,071,320 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.3300 fall in that time frame. In the last twenty days, the average volume was 14,803,320, while in the previous 50 days, it was 8,465,727.
Since last month, NKTR stock rose 27.55%. Shares of the company fell to $0.5051 on 07/26/23, the lowest level in the past month. A 52-week high of $4.79 was reached on 02/07/23 after having rallying from a 52-week low of $0.51. Since the beginning of this year, NKTR’s stock price has dropped by -68.14% or -$1.5400, and marked a new high 15 times. However, the stock has declined by -84.97% since its 52-week high.
NKTR stock investors should be aware that Nektar Therapeutics (NKTR) stock had its last reported insider trading activity 2 days ago on Aug 16. ROBIN HOWARD W, the President & CEO of the company, disposed of 19,998 shares for $0.78 on Aug 16. It resulted in a $15,598 divestment by the insider. Zalevsky Jonathan sold 9,703 shares at an average price of $0.78 on Aug 16. The insider now owns 283,685 shares following the transaction. On Aug 16, Chief Legal Officer Wilson Mark Andrew sold 7,221 shares at $0.78 apiece. The transaction was valued at $5,632.
Valuation Metrics
The stock’s beta is 0.88. Besides these, the trailing price-to-sales (P/S) ratio of 1.75, the price-to-book (PB) ratio of 0.69.
Financial Health
In the three months ended June 29, Nektar Therapeutics’s quick ratio stood at 8.30, while its current ratio was 8.70, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 71.20% percent. Based on annual data, NKTR earned $70.42 million in gross profit and brought in $92.06 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -103.50%. Return on equity (ROE) for the past 12 months was -100.90%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. NKTR’s revenue fell -5.32% to $21.59 million during the quarter, while net income inched up to $20.5 million. While analysts expected Nektar Therapeutics to report -$0.28 quarterly earnings, the actual figure was -$0.27 per share, beating the consensus estimate by 3.60%. During the quarter, the company generated -$53.45 million in EBITDA. The liabilities of Nektar Therapeutics were 297.32 million at the end of its most recent quarter ended June 29, and its total debt was $124.75 million. The value of shareholders’ equity is $190.12 million.
Technical Picture
This quick technical analysis looks at Nektar Therapeutics’s (NKTR) price momentum. With a historical volatility rate of 364.90%, the RSI 9-day stood at 47.23% on 17 August.
With respect to its five-day moving average, the current Nektar Therapeutics price is down by -31.43% percent or -$0.3300. At present, NKTR shares trade +30.91% above its 20-day simple moving average and +0.28% percent above its 100-day simple moving average. However, the stock is currently trading approximately +18.19% above its SMA50 and -80.85% below its SMA200.
Stochastic coefficient K was 42.30% and Stochastic coefficient D was 49.08%, while ATR was 0.1141. Given the Stochastic reading of 34.84% for the 14-day period, the RSI (14) reading has been calculated as 50.78%. As of today, the MACD Oscillator reading stands at -0.1270.
Analyst Ratings
Jefferies upgraded its rating on Nektar Therapeutics (NASDAQ: NKTR) to a Hold in a note to investors on May 10, 2023. The analysts firm previously had an Underperform rating on the stock.Nektar Therapeutics (NKTR) has been rated Hold by analysts. According to 1 brokerage firm, NKTR is a sell, and 6 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate Nektar Therapeutics stock as buy, with 0 recommending it as overweight.
With a median target price of $1.75, the current consensus forecast for the stock is $0.60 – $6.00. Based on these forecasts, analysts predict Nektar Therapeutics (NKTR) will achieve an average price target of $2.35.
